- Summit, Merck must navigate new regulatory terrain in China-first cancer landscapeSummit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…BioSpace · 1d ago↗ source
- FDA has recommitted to adcomms—but to what end?The FDA will hold advisory committee meetings this week for previously rejected investigational therapies from Replimune and Capricor Therapeutics. Some industry leaders were surprised the meetings…BioSpace · 1d ago↗ source
- Labcorp launches DTC ‘Genetic Health Panel’ to seek out multiple diseasesLabcorp is launching the Marker by Labcorp Genetic Health Panel, a new direct-to-consumer genetic testing tool that analyzes 163 genes to determine patients’ risk of over 100 hereditary health cond…